【摘要】 目的：评价头孢哌酮钠／他唑巴坦钠（８：１）的体外抗菌活性和影响抗菌活性的因素。方法：采用琼脂平板二倍稀释法测定头孢哌酮钠／他唑巴坦钠（８：１）复方制剂对临床分离致病菌的体外抗菌作用，并与头孢哌酮钠、头孢哌酮钠／舒巴坦钠（１：１）和哌拉西林钠／他唑巴坦钠（８：１）进行比较。结果：头孢哌酮钠与他唑巴坦销以８：１配比，体外抗菌谱较头孢哌酮扩大，对产酶菌株，二者合用可不同程度的提高头孢哌酮单用的体外抗菌活性，与头孢哌酮钠／舒巴坦钠（１：１）和哌拉西林钠／他唑巴坦钠（８：１）的抗菌活性相似。杀菌活性的结果显示头孢哌酮钠与他唑巴坦钠以８：１配比合用对所测产酶菌的ＭＢＣ９０的值是ＭＩＣ９０值的４—８倍，提示头孢哌酮销与他唑巴坦钠以８：１配比合用对产酶菌有较强的杀菌活性。ＭＩＣ值随细菌接种量的增高而增高；对Ｇ杆菌的ＭＩＣ值随ｐＨ值升高而下降，对金葡菌、表葡菌的ＭＩＣ值随ＰＨ值升高而上升；ＭＩＣ值随血清蛋白浓度的提高而增高。结论：他唑巴坦增强了头孢哌酮对B- 内酰胺酶的稳定性，头孢哌酮钠／他唑巴钠（８：１）有较强的抗菌和杀菌活性。细菌所处的条件不同会影响其抗菌活性。更多还原

【Abstract】 OBJECTIVE: To evaluate the in-vitro antibacterial activity of combinations of cefoperazone(CPZ)-tazobactam(TAZ) according to ratio 8:1 and factors of impact on antibacterial achvity. METHODS: The minimal inhibitory concentrations (MICs) of CPZ/TAZ (8:l) to the bacteria isolated from clinical department and producing B-actamases were determined by standard agar dilution method and compared with the MICs of CPZ, cefoperazone (CPZ)/sulbactam (SUB) (l:1) and piperacillin (PIPC)/TAZ) (8:1). RESULTS: The antibacterial activity of CPZ combined with TAZ was superior to CPZ alone and similar to CPZ/SUB(1:1) and PIPC/TAZ(8: 1). The result of in-vitro bactericidal activity showed the minimal bactericidal concentrations (MBC90) of CPZ/TAZ of 8:1 were 4 to 8 higher than MIC90 against the detected bacteria. The MIC of CP/TAZ (8:1) increased with increase of concentration of serum albumin and bacteria incubated in media. The MICs of CPZ/TAZ (8:1) to MSSA and MSCoNS increased and The MICs of it against gram-negative bacilli decreased with increase of pH in media. CONCLUSION: The stability of the combinations of CPZ with TAZ to B-lactamases is improved and antibacterial and bactericidal activities are of cefoperazone enhanced by tazobactam. Different condihons in media can influence on antimicrobial activity of CPNAZ.更多还原